Visit the National Instruments web site
Click on the advert above to visit the company web site

Product category: Analogue and Mixed Signal ICs
News Release from: AMI Semiconductor | Subject: Medical semiconductors
Edited by the Electronicstalk Editorial Team on 08 November 2006

Medical semiconductors help treat
epilepsy

Request your FREE weekly copy of the Electronicstalk email newsletter. News about Analogue and Mixed Signal ICs and more every issue. Click here for details.

Implantable medical device company NeuroPace has leveraged AMI Semiconductor's medical semiconductor expertise for an implantable epilepsy device, the Responsive Neurostimulator (RNS) system.

Implantable medical device company NeuroPace has leveraged AMI Semiconductor's medical semiconductor expertise for an implantable epilepsy device, the Responsive Neurostimulator (RNS) system NeuroPace's RNS is specifically designed for the treatment of medically refractory partial onset epilepsy and includes implantable and external products, accessories and tools

In addition to treating epilepsy, responsive neurostimulation holds the promise of treating other disabling medical disorders that impact the quality of life for millions of patients around the world.

In treating epilepsy, the RNS is designed to detect abnormal electrical activity in the brain and respond by delivering electrical stimulation to normalise brain activity before the patient experiences seizure symptoms.

The RNS is implanted in the cranium and connected to one or two leads that are implanted near the patient's seizure focus.

By targeting electrical stimulation to specific nervous system sites, the RNS is designed to suppress seizures and minimise the patient's use of anti-epileptic medication and the side effects commonly associated with these medications.

"We evaluated the major participants in the implantable medical semiconductor design business", said Frank Fischer, CEO at NeuroPace.

"AMIS has the proven expertise in development of advanced mixed-signal technologies for innovative medical applications".

"The company's production capabilities and experience are an excellent fit for the critical technical requirements and support necessary for our RNS system".

"The implantable neurostimulation device market is a key strategic focus for our medical semiconductor solutions", said Robert Tong, Senior Vice President of Medical and Wireless Products for AMIS.

"Based on our research and the volume of new technology solutions being developed, we believe this is a market that will grow exponentially over the next few years".

"It offers high potential growth for AMIS, who has been developing and manufacturing mixed-signal and wireless solutions for implantable devices for more than 10 years".

"We are very aware of the constraints that must be considered when designing semiconductors for implantation in the human body and we are excited to partner with an innovator like NeuroPace to use our knowledge to help improve the lives of those afflicted with epilepsy".

NeuroPace is currently sponsoring an FDA approved investigational study of the implantable RNS system to suppress seizures in patients with drug refractory epilepsy.

AMI Semiconductor: contact details and other news
Email this article to a colleague
Register for the free Electronicstalk email newsletter
Electronicstalk Home Page

Search the Pro-Talk network of sites

Visit the National Instruments web site